Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
Standard
Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis". / Lohse, Ansgar W; Sebode, Marcial; Vesterhus, Mette.
In: J HEPATOL, Vol. 74, No. 3, 03.2021, p. 755-756.Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research
Harvard
Lohse, AW, Sebode, M & Vesterhus, M 2021, 'Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"', J HEPATOL, vol. 74, no. 3, pp. 755-756. https://doi.org/10.1016/j.jhep.2020.11.031
APA
Lohse, A. W., Sebode, M., & Vesterhus, M. (2021). Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis". J HEPATOL, 74(3), 755-756. https://doi.org/10.1016/j.jhep.2020.11.031
Vancouver
Lohse AW, Sebode M, Vesterhus M. Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis". J HEPATOL. 2021 Mar;74(3):755-756. https://doi.org/10.1016/j.jhep.2020.11.031
Bibtex
@article{c16b33c0733f4514857c6a0fce763b50,
title = "Reply to: {"}Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis{"}",
author = "Lohse, {Ansgar W} and Marcial Sebode and Mette Vesterhus",
year = "2021",
month = mar,
doi = "10.1016/j.jhep.2020.11.031",
language = "English",
volume = "74",
pages = "755--756",
journal = "J HEPATOL",
issn = "0168-8278",
publisher = "Elsevier",
number = "3",
}
RIS
TY - JOUR
T1 - Reply to: "Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis"
AU - Lohse, Ansgar W
AU - Sebode, Marcial
AU - Vesterhus, Mette
PY - 2021/3
Y1 - 2021/3
U2 - 10.1016/j.jhep.2020.11.031
DO - 10.1016/j.jhep.2020.11.031
M3 - Other (editorial matter etc.)
C2 - 33309116
VL - 74
SP - 755
EP - 756
JO - J HEPATOL
JF - J HEPATOL
SN - 0168-8278
IS - 3
ER -
